LifeScienceXchange

LifeScienceXchange offers actionable market insights, technology showcases, thought leadership and essential news, all in a condensed and curated video format. LifeScienceXchange multiplies the impact of biologics and immunotherapy R&D, bringing new treatments to patients faster.

Latest News and Commentary

Top 25 of ’25: NextGen Biomed eBook

Curated insight from the leaders shaping biologics and immunotherapy

Bristol Myers Squibb Buys Orbital Therapeutics in $1.5b Deal

Tom Cohen Digital Publisher, Oxford Global

Technology Spotlight

Three Innovations for Green and Controlled Peptide Manufacture

Fabien Rousset Director Global Innovation, PolyPeptide

Market Insight

The Digital Transformation of Oligonuleotide Development

Martin Olbrich Principal Scientist, Process Research, Roche

Market Insight

Targeting Melanoma with the SCIB1 Vaccine

Samantha Paston Head of Translational Research, Scancell

NGB LSX - Connect with Peers

Latest Technology Spotlights

A Novel Engineered CHO Host Cell Line For High-Titer Production Of Biopharmaceuticals

One Reactor To Rule Them All: A Novel Bionic Bioreactor for Sensitive Stem & Immune-Cells

Assessment Of Tumour Cell Susceptibility To Killing By Antigen-Specific And Nonspecific CD8+T Cells

Accelerate Your Biologics Design with Computational Modelling Tools

Latest News

Delivering Next Generation Regenerative Medicine

Top 25 of ’25: NextGen Biomed eBook

Ianalumab Effective for Immune Thrombocytopenia in Phase III

Thought Leadership

Delivering Next Generation Regenerative Medicine

Molly Stevens Professor of Bionanoscience, University of Oxford

Roger Barker Professor, University of Cambridge

Andrea Serio Group Leader, Francis Crick Institute

George Malliaras Prince Philip Professor of Technology, University of Cambridge

Animal Free 3D Cell Culture and Organoid Growth: Interview with Aline Miller, University of Manchester

Aline Miller Professor of Biomolecular Engineering, University of Manchester

Chemical Engineering Of Oligonucleotides: Interview with Sudhir Agrawal, ARNAY Sciences

Sudhir Agrawal Founder & President & Affiliate Professor, ARNAY Sciences & UMass Chan Medical School

Market Insight: Across Modalities

An All Stakeholder Approach To Cell & Gene Therapy

Scaling Up Complex Organoid Models: Challenges And Solutions

Challenges and Solutions in the Purification of Oligonucleotides

Protein Corona and Freeze-Thaw Stability in Lipid Nanoparticles

Pre-Clinical Considerations For Development Of ADCs

How ‘Proximity Medicines’ Are Transforming Pharmacotherapy

Snakebite Medicines: Venom Derived Peptides for Therapeutic Indications

AI-Powered Peptide Design: Transforming Drug Discovery with Machine Learning

Cell-Free Cancer Vaccines Developed in Two Weeks

Potency Testing in RNA Therapeutics